Skip to main content
Erschienen in: Wiener klinische Wochenschrift 23-24/2022

27.10.2022 | original article

Early administration of remdesivir may reduce mortality in hospitalized COVID-19 patients

A propensity score matched analysis

verfasst von: Mario Karolyi, Lukas Kaltenegger, Erich Pawelka, Avelino Kuran, Moritz Platzer, David Totschnig, Franz Koenig, Wolfgang Hoepler, Hermann Laferl, Sara Omid, Tamara Seitz, Marianna Traugott, Sigrun Arthofer, Lea Erlbeck, Stefan Jaeger, Alina Kettenbach, Alice Assinger, Christoph Wenisch, Alexander Zoufaly

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 23-24/2022

Einloggen, um Zugang zu erhalten

Summary

Background

Remdesivir is the only antiviral agent approved for the treatment of hospitalized coronavirus disease 2019 (COVID-19) patients requiring supplemental oxygen. Studies show conflicting results regarding its effect on mortality.

Methods

In this single center observational study, we included adult hospitalized COVID-19 patients. Patients who were treated with remdesivir were compared to controls. Remdesivir was administered for 5 days. To adjust for any imbalances in our cohort, a propensity score matched analysis was performed. The aim of our study was to analyze the effect of remdesivir on in-hospital mortality and length of stay (LOS).

Results

After propensity score matching, 350 patients (175 remdesivir, 175 controls) were included in our analysis. Overall, in-hospital mortality was not significantly different between groups remdesivir 5.7% [10/175] vs. control 8.6% [15/175], hazard ratio 0.50, 95% confidence interval (CI) 0.22–1.12, p = 0.091. Subgroup analysis showed a significant reduction of in-hospital mortality in patients who were treated with remdesivir ≤ 7 days of symptom onset remdesivir 4.2% [5/121] vs. control 10.4% [13/125], hazard ratio 0.26, 95% CI 0.09 to 0.75, p = 0.012 and in female patients remdesivir 2.9% [2/69] vs. control 12.2% [9/74], hazard ratio 0.18 95%CI 0.04 to 0.85, p = 0.03. Patients in the remdesivir group had a significantly longer LOS (11 days vs. 9 days, p = 0.046).

Conclusion

Remdesivir did not reduce in-hospital mortality in our whole propensity score matched cohort, but subgroup analysis showed a significant mortality reduction in female patients and in patients treated within ≤ 7 days of symptom onset. Remdesivir may reduce mortality in patients who are treated in the early stages of illness.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
7.
Zurück zum Zitat Kaka AS, MacDonald R, Greer N, et al. Major update: Remdesivir for adults with COVID-19 : a living systematic review and meta-analysis for the American college of physicians practice points. Ann Intern Med. 2021;174(5):663–72. https://doi.org/10.7326/M20-8148.CrossRef Kaka AS, MacDonald R, Greer N, et al. Major update: Remdesivir for adults with COVID-19 : a living systematic review and meta-analysis for the American college of physicians practice points. Ann Intern Med. 2021;174(5):663–72. https://​doi.​org/​10.​7326/​M20-8148.CrossRef
9.
Zurück zum Zitat R Core Team. R: A language and environment for statistical computing. 2020. R Core Team. R: A language and environment for statistical computing. 2020.
15.
16.
Zurück zum Zitat Ader F, Bouscambert-Duchamp M, Hites M, et al. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial. Lancet Infect Dis. 2021;3099(21):485–480. https://doi.org/10.1016/S1473-3099(21)00485-0.CrossRef Ader F, Bouscambert-Duchamp M, Hites M, et al. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial. Lancet Infect Dis. 2021;3099(21):485–480. https://​doi.​org/​10.​1016/​S1473-3099(21)00485-0.CrossRef
19.
Zurück zum Zitat Muthuri SG, Venkatesan S, Myles PR, et al. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. Lancet Respir Med. 2014;2(5):395–404.CrossRef Muthuri SG, Venkatesan S, Myles PR, et al. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. Lancet Respir Med. 2014;2(5):395–404.CrossRef
20.
Zurück zum Zitat Doll MK, Winters N, Boikos C, et al. Safety and effectiveness of neuraminidase inhibitors for influenza treatment, prophylaxis, and outbreak control: a systematic review of systematic reviews and/or meta-analyses. J Antimicrob Chemother. 2017;72(11):2990–3007. https://doi.org/10.1093/jac/dkx271.CrossRef Doll MK, Winters N, Boikos C, et al. Safety and effectiveness of neuraminidase inhibitors for influenza treatment, prophylaxis, and outbreak control: a systematic review of systematic reviews and/or meta-analyses. J Antimicrob Chemother. 2017;72(11):2990–3007. https://​doi.​org/​10.​1093/​jac/​dkx271.CrossRef
Metadaten
Titel
Early administration of remdesivir may reduce mortality in hospitalized COVID-19 patients
A propensity score matched analysis
verfasst von
Mario Karolyi
Lukas Kaltenegger
Erich Pawelka
Avelino Kuran
Moritz Platzer
David Totschnig
Franz Koenig
Wolfgang Hoepler
Hermann Laferl
Sara Omid
Tamara Seitz
Marianna Traugott
Sigrun Arthofer
Lea Erlbeck
Stefan Jaeger
Alina Kettenbach
Alice Assinger
Christoph Wenisch
Alexander Zoufaly
Publikationsdatum
27.10.2022
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe 23-24/2022
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-022-02098-9

Weitere Artikel der Ausgabe 23-24/2022

Wiener klinische Wochenschrift 23-24/2022 Zur Ausgabe